1
|
Jongbloed M, Bartolomeo V, Steens M, Dursun S, van de Lisdonk T, De Ruysscher DKM, Hendriks LEL. Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population. Eur J Cancer 2023; 190:112947. [PMID: 37451182 DOI: 10.1016/j.ejca.2023.112947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 06/12/2023] [Accepted: 06/12/2023] [Indexed: 07/18/2023]
Abstract
The standard first-line treatment for non-oncogene driven metastatic non-small cell lung cancer (NSCLC) is an immune checkpoint inhibitor (ICI) based strategy. Although guidelines increasingly advise adding local radical treatment (LRT) to patients with synchronous oligometastatic (sOMD) NSCLC responding to systemic therapy, this recommendation is based on the studies without ICI. Furthermore, the majority of published oligometastatic studies were not on an intention-to-treat basis, resulting in selection bias. Moreover, staging Positron Emission Tomography-Computed Tomography (PET-CT) and brain imaging were often not mandatory and definitions of oligometastatic were heterogeneous. Therefore, this study focused on a single centre retrospective series, including all adequately staged patients with sOMD NSCLC according to the European Organisation for Research and Treatment of Cancer definition (maximum of 5 metastases in 3 organs) that were treated with induction (chemo)-ICI and compared outcomes to those treated with chemotherapy only, with and without LRT. The primary end-points were median progression-free survival (PFS) and overall survival (OS) for patients treated with induction (chemo)-ICI versus chemotherapy. Out of 68 included patients, 38 (56%) eventually received LRT. With a median follow-up of 26.7 months, the median PFS was 19.0 months for (chemo)-ICI (n = 18) versus 6.8 for chemotherapy-only (n = 50) (HR 0.5, p = 0.03), the median OS was 19.3 versus 15.7 months, respectively (HR 0.8, p = 0.4). In patients having received LRT, median PFS was 19.0 months for (chemo)-ICI versus 8.3 for chemotherapy-only (HR 0.6, p = 0.2). In conclusion, an ICI-based systemic treatment is feasible and may result in superior survival outcomes. This should be investigated in prospective trials. Strategies to improve response rates to systemic treatment are also needed.
Collapse
Affiliation(s)
- M Jongbloed
- Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands
| | - V Bartolomeo
- Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical Surgical, Diagnostic and Pediatric Sciences, Pavia University, Pavia, Italy; Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW-School for Oncology and Reproduction (GROW), Maastricht, the Netherlands
| | - M Steens
- Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands
| | - S Dursun
- Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands
| | - T van de Lisdonk
- Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, the Netherlands
| | - D K M De Ruysscher
- Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW-School for Oncology and Reproduction (GROW), Maastricht, the Netherlands
| | - L E L Hendriks
- Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.
| |
Collapse
|
2
|
Kivit CMHJ, Groen K, Jongbloed M, Linssen CFM, van Loo A, van Gorp ECM, van Nieuwkoop S, den Hoogen BGV, Kruif MDD. An off-season outbreak of human metapneumovirus infections after ending of a COVID-19 lockdown. J Infect 2022; 84:722-746. [PMID: 35123959 PMCID: PMC8847107 DOI: 10.1016/j.jinf.2022.01.042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 01/29/2022] [Indexed: 10/30/2022]
|
3
|
Jongbloed M, Bax J, Lamb H, Dirksen M, Zeppenfeld K, Van der Wall E, De Roos A, Schalij M. 942 A head to head comparison of multi-slice computed tomography versus intracardiac echocardiography to evaluate pulmonary vein anatomy prior to radiofrequency catheter ablation of atrial fibrillation. Europace 2005. [DOI: 10.1016/eupace/7.supplement_1.226-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
| | - J.J. Bax
- Leiden University Medical Center, Cardiology, Leiden, Netherlands
| | - H.J. Lamb
- Leiden University Medical Center, Radiology, Leiden, Netherlands
| | - M.S. Dirksen
- Leiden University Medical Center, Radiology, Leiden, Netherlands
| | - K. Zeppenfeld
- Leiden University Medical Center, Cardiology, Leiden, Netherlands
| | | | - A. De Roos
- Leiden University Medical Center, Radiology, Leiden, Netherlands
| | - M.J. Schalij
- Leiden University Medical Center, Cardiology, Leiden, Netherlands
| |
Collapse
|